Single agent activity of rhizoxin in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group
1996
Rhizoxin for Non-Small-Cell Lung Cancer
Sample size: 31
publication
Evidence: moderate
Author Information
Author(s): S Kaplan, AR Hanauske, N Pavlidis, U Bruntsch, A te Velde, J Wanders, B Heinrich, J Verweij
Hypothesis
Does rhizoxin show activity in patients with advanced non-small-cell lung cancer?
Conclusion
Rhizoxin as a single agent shows activity in patients with advanced non-small-cell lung cancer.
Supporting Evidence
- Four partial responses were observed in 27 evaluable patients.
- Thirteen patients showed stabilization of their disease.
- The median duration of response was 7 months.
- The median survival from the start of treatment was 6 months.
Takeaway
Rhizoxin is a new medicine that helps some people with lung cancer feel better and live longer.
Methodology
A multicentre phase II trial was conducted with 31 chemotherapy-naive patients treated with rhizoxin.
Limitations
The study had a small sample size and did not include weekly laboratory tests for toxicity.
Participant Demographics
Patients were aged 27 to 76, with a mix of male and female participants.
Statistical Information
Confidence Interval
95% CI 4.2-33.7%
Want to read the original?
Access the complete publication on the publisher's website